600867.SS SHH
Tonghua Dongbao Pharmaceutical Co., Ltd.
1W: -0.1%
1M: -3.1%
3M: -5.2%
YTD: -11.4%
1Y: -6.8%
3Y: -17.2%
5Y: -24.9%
¥7.86 ($1.17)
+0.18 (+2.34%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$460M
-46.6% ▼
5Y CAGR: -16.8%
Capital Expenditures
$569M
-63.4% ▼
5Y CAGR: +14.2%
Free Cash Flow
-$109M
-121.2% ▼
Dividends Paid
$495M
+0.1% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$518M
-263.7% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $930M | $1.3B | $1.6B | $1.2B | -$44M |
| Depreciation & Amort. | $155M | $144M | $151M | $186M | $205M |
| Stock-Based Comp. | $4M | $48M | $34M | -$17M | $0 |
| Change in Working Capital | $83M | -$48M | $73M | -$486M | $180M |
| Other Non-Cash Items | $21M | -$312M | -$980M | $11M | $218M |
| Operating Cash Flow | $1.2B | $1.1B | $863M | $862M | $460M |
| — Investing Activities — | |||||
| Capital Expenditures | -$480M | -$601M | -$492M | -$348M | -$569M |
| Acquisitions (Net) | -$28M | $20M | $0 | $0 | $67M |
| Investment Purchases | -$510M | -$844M | -$1.2B | -$238M | -$230M |
| Investment Sales | $400M | $1.5B | $2.0B | $241M | $163M |
| Other Investing | $1M | $0 | -$4M | $24M | $0 |
| Investing Cash Flow | -$617M | $34M | $344M | -$322M | -$569M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$125M | $0 | $0 | $150M | $520M |
| Stock Repurchased | -$59M | $0 | $0 | $0 | $0 |
| Dividends Paid | -$404M | -$425M | -$1.1B | -$496M | -$495M |
| Other Financing | $48M | -$271M | -$188M | $122M | -$441M |
| Financing Cash Flow | -$481M | -$696M | -$1.3B | -$224M | -$409M |
| Net Change in Cash | $95M | $473M | -$77M | $316M | -$518M |
| Cash End of Period | $392M | $865M | $788M | $1.1B | $587M |
| Free Cash Flow | $713M | $534M | $371M | $513M | -$109M |